Accelerating Development and Building Trust in COVID-19 Vaccines With Public Quality Standards

Accelerating Development and Building Trust in COVID-19 Vaccines With Public Quality Standards

Contract Manufacturing

Information

Along with speed and leveraging different strategies, including live attenuated viruses, viral vectors, proteins, and DNA or RNA vaccines, we need to ensure that new vaccines and treatments are trusted by healthcare providers and ultimately patients. Jaap Venema, Ph.D., USP Chief Science Officer, discusses how trust can be built to encourage patient adoption of new vaccines, particularly for COVID-19.
United States PharmacopeiaUSP is an independent, nonprofit, scientific organization that collaborates with the world's top experts in health and science to develop quality standards for medicines, dietary supplements, and food ingredients. Through our standards, advocacy and education, USP helps increase the availability of quality medicines, supplements and food for billions of people worldwide. Learn more about how we help support the development and distribution of vaccines at www.usp.org/trust-accelerated.

Log in